Cisplatin enhances protein <em>O</em>‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells

Wang,Di; Wu,Jiaan; Wang,Dandan; Huang,Xiaoyan; Zhang,Naining; Shi,Yikang

doi:10.3892/ijo.2021.5207

Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells

Authors:
- Di Wang
- Jiaan Wu
- Dandan Wang
- Xiaoyan Huang
- Naining Zhang
- Yikang Shi
View Affiliations

Affiliations: National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao, Shandong 266237, P.R. China
Published online on: April 8, 2021 https://doi.org/10.3892/ijo.2021.5207
Article Number: 27

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA). Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors. However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells. In the present study, to investigate whether cisplatin alters protein O‑GlcNAcylation and to explore whether protein O‑GlcNAc modification affects the antitumor activity of cisplatin, experiments were performed in vitro and in vivo. The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo. Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells. Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells. On the contrary, the activation of OGA decreased in response to cisplatin exposure in H1299 cells. Cisplatin inhibited the activity of AMP‑activated protein kinase (AMPK) by decreasing the AMP/ATP ratio. The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1. Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc). However, alterations in the O‑GlcNAc levels by the inhibition of OGT and OGA did not affect the sensitivity of lung cancer cells to cisplatin. On the whole, the present study demonstrates that cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in vitro and in vivo.

View Figures

View References

1	Wells L and Hart GW: O-GlcNAc turns twenty: Functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. FEBS Lett. 546:154–158. 2003. View Article : Google Scholar : PubMed/NCBI
2	Joiner CM, Li H, Jiang J and Walker S: Structural characterization of the O-GlcNAc cycling enzymes: Insights into substrate recognition and catalytic mechanisms. Curr Opin Struct Biol. 56:97–106. 2019. View Article : Google Scholar : PubMed/NCBI
3	Nie H and Yi W: O-GlcNAcylation, a sweet link to the pathology of diseases. J Zhejiang Univ Sci B. 20:437–448. 2019. View Article : Google Scholar : PubMed/NCBI
4	Hanover JA, Chen W and Bond MR: O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle. J Bioenerg Biomembr. 50:155–173. 2018. View Article : Google Scholar : PubMed/NCBI
5	Hart GW: Nutrient regulation of signaling and transcription. J Biol Chem. 294:2211–2231. 2019. View Article : Google Scholar : PubMed/NCBI
6	Martinez MR, Dias TB, Natov PS and Zachara NE: Stress-induced O-GlcNAcylation: an adaptive process of injured cells. Biochem Soc Trans. 45:237–249. 2017. View Article : Google Scholar : PubMed/NCBI
7	Lee A, Miller D, Henry R, Paruchuri VD, O'Meally RN, Boronina T, Cole RN and Zachara NE: Combined anti-body/Lectin enrichment identifies extensive changes in the O-GlcNAc sub-proteome upon oxidative stress. J Proteome Res. 15:4318–4336. 2016. View Article : Google Scholar : PubMed/NCBI
8	Groves JA, Maduka AO, O'Meally RN, Cole RN and Zachara NE: Fatty acid synthase inhibits the O-GlcNAcase during oxidative stress. J Biol Chem. 292:6493–6511. 2017. View Article : Google Scholar : PubMed/NCBI
9	Zachara NE, Molina H, Wong KY, Pandey A and Hart GW: The dynamic stress-induced 'O-GlcNAc-ome' highlights functions for O-GlcNAc in regulating DNA damage/repair and other cellular pathways. Amino Acids. 40:793–808. 2011. View Article : Google Scholar
10	Chen SH and Chang JY: New insights into mechanisms of cisplatin resistance: From tumor cell to microenvironment. Int J Mol Sci. 20:41362019. View Article : Google Scholar :
11	Chen W, Do KC, Saxton B, Leng S, Filipczak P, Tessema M, Belinsky SA and Lin Y: Inhibition of the hexosamine biosynthesis pathway potentiates cisplatin cytotoxicity by decreasing BiP expression in non-small-cell lung cancer cells. Mol Carcinog. 58:1046–1055. 2019. View Article : Google Scholar : PubMed/NCBI
12	Zhou F, Yang X, Zhao H, Liu Y, Feng Y, An R, Lv X, Li J and Chen B: Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. Theranostics. 8:5200–5212. 2018. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
14	Kang JG, Park SY, Ji S, Jang I, Park S, Kim HS, Kim SM, Yook JI, Park YI, Roth J and Cho JW: O-GlcNAc protein modification in cancer cells increases in response to glucose deprivation through glycogen degradation. J Biol Chem. 284:34777–34784. 2009. View Article : Google Scholar : PubMed/NCBI
15	Taylor RP, Geisler TS, Chambers JH and McClain DA: Up-regulation of O-GlcNAc transferase with glucose deprivation in HepG2 cells is mediated by decreased hexosamine pathway flux. J Biol Chem. 284:3425–3432. 2009. View Article : Google Scholar :
16	Eguchi S, Oshiro N, Miyamoto T, Yoshino K, Okamoto S, Ono T, Kikkawa U and Yonezawa K: AMP-activated protein kinase phosphorylates glutamine: Fructose-6-phosphate amidotransferase 1 at Ser243 to modulate its enzymatic activity. Genes Cells. 14:179–189. 2009. View Article : Google Scholar : PubMed/NCBI
17	Nöt LG, Brocks CA, Vámhidy L, Marchase RB and Chatham JC: Increased O-linked beta-N-acetylglucosamine levels on proteins improves survival, reduces inflammation and organ damage 24 h after trauma-hemorrhage in rats. Crit Care Med. 38:562–571. 2010. View Article : Google Scholar
18	Chen R, Lai LA, Sullivan Y, Wong M, Wang L, Riddell J, Jung L, Pillarisetty VG, Brentnall TA and Pan S: Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer. Sci Rep. 7:79502017. View Article : Google Scholar : PubMed/NCBI
19	Asthana A, Ramakrishnan P, Vicioso Y, Zhang K and Parameswaran R: Hexosamine biosynthetic pathway inhibition leads to AML cell differentiation and cell death. Mol Cancer Ther. 17:2226–2237. 2018. View Article : Google Scholar : PubMed/NCBI
20	Zibrova D, Vandermoere F, Göransson O, Peggie M, Mariño KV, Knierim A, Spengler K, Weigert C, Viollet B, Morrice NA, et al: GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis. Biochem J. 474:983–1001. 2017. View Article : Google Scholar
21	Lin SC and Hardie DG: AMPK: Sensing glucose as well as cellular energy status. Cell Metab. 27:299–313. 2018. View Article : Google Scholar
22	Patel BA, D'Amico TL and Blagg BSJ: Natural products and other inhibitors of F₁F_O ATP synthase. Eur J Med Chem. 207:1127792020. View Article : Google Scholar
23	Zhou W and Faraldo-Gómez JD: Membrane plasticity facilitates recognition of the inhibitor oligomycin by the mitochondrial ATP synthase rotor. Biochim Biophys Acta Bioenerg. 1859:789–796. 2018. View Article : Google Scholar : PubMed/NCBI
24	Zachara NE, O'Donnell N, Cheung WD, Mercer JJ, Marth JD and Hart GW: Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J Biol Chem. 279:30133–30142. 2004. View Article : Google Scholar : PubMed/NCBI
25	Pan X, Wilson M, Mirbahai L, McConville C, Arvanitis TN, Griffin JL, Kauppinen RA and Peet AC: In vitro metabonomic study detects increases in UDP-GlcNAc and UDP-GalNAc, as early phase markers of cisplatin treatment response in brain tumor cells. J Proteome Res. 10:3493–3500. 2011. View Article : Google Scholar : PubMed/NCBI
26	Duarte IF, Ladeirinha AF, Lamego I, Gil AM, Carvalho L, Carreira IM and Melo JB: Potential markers of cisplatin treatment response unveiled by NMR metabolomics of human lung cells. Mol Pharm. 10:4242–4251. 2013. View Article : Google Scholar : PubMed/NCBI
27	Duarte IF, Lamego I, Marques J, Marques MP, Blaise BJ and Gil AM: Nuclear magnetic resonance (NMR) study of the effect of cisplatin on the metabolic profile of MG-63 osteosarcoma cells. J Proteome Res. 9:5877–5886. 2010. View Article : Google Scholar : PubMed/NCBI
28	Yang C, Peng P, Li L, Shao M, Zhao J, Wang L, Duan F, Song S, Wu H, Zhang J, et al: High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer. Sci Rep. 6:390442016. View Article : Google Scholar : PubMed/NCBI
29	Li L, Shao M, Peng P, Yang C, Song S, Duan F, Jia D, Zhang M, Zhao J, Zhao R, et al: High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget. 8:19205–19217. 2017. View Article : Google Scholar : PubMed/NCBI
30	Chang Q, Su K, Baker JR, Yang X, Paterson AJ and Kudlow JE: Phosphorylation of human glutamine: Fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme activity. J Biol Chem. 275:21981–21987. 2000. View Article : Google Scholar : PubMed/NCBI
31	Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, Giri B, Ferrantella A, Dudeja V, Saluja A and Banerjee S: Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 130:451–465. 2020. View Article : Google Scholar :
32	Lemberg KM, Vornov JJ, Rais R and Slusher BS: We're Not 'DON' Yet: Optimal dosing and prodrug delivery of 6-Diazo-5-oxo-L-norleucine. Mol Cancer Ther. 17:1824–1832. 2018. View Article : Google Scholar : PubMed/NCBI
33	Laczy B, Fülöp N, Onay-Besikci A, Des Rosiers C and Chatham JC: Acute regulation of cardiac metabolism by the hexosamine biosynthesis pathway and protein O-GlcNAcylation. PLoS One. 6:e184172011. View Article : Google Scholar : PubMed/NCBI
34	Hudson CD, Savadelis A, Nagaraj AB, Joseph P, Avril S, DiFeo A and Avril N: Altered glutamine metabolism in platinum resistant ovarian cancer. Oncotarget. 7:41637–41649. 2016. View Article : Google Scholar : PubMed/NCBI
35	Zhao JG, Ren KM and Tang J: Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism. Tumour Biol. 35:12305–12315. 2014. View Article : Google Scholar : PubMed/NCBI
36	Yang X and Qian K: Protein O-GlcNAcylation: Emerging mechanisms and functions. Nat Rev Mol Cell Biol. 18:452–465. 2017. View Article : Google Scholar : PubMed/NCBI
37	Haltiwanger RS, Grove K and Philipsberg GA: Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate. J Biol Chem. 273:3611–3617. 1998. View Article : Google Scholar : PubMed/NCBI
38	Wang L, Chen S, Zhang Z, Zhang J, Mao S, Zheng J, Xuan Y, Liu M, Cai K, Zhang W, et al: Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer. BMC Cancer. 18:11412018. View Article : Google Scholar : PubMed/NCBI